Kardigan has reported Phase 2 data for tonlamarsen, its investigational antisense oligonucleotide targeting angiotensinogen, in patients with uncontrolled hypertension despite treatment with at least two antihypertensive medicines. Presented at ACC.26 and published in the Journal of the American College of Cardiology, the KARDINAL trial showed statistically significant reductions in plasma angiotensinogen levels and clinically meaningful reductions in office systolic blood pressure, while also supporting the company’s plan to move into a Phase 2b study in acute severe hypertension after hospitalization.
What makes these data more interesting than a routine mid-stage hypertension update is not the headline blood pressure reduction alone, but the strategic reframing of where tonlamarsen may fit. Kardigan is no longer simply arguing that monthly suppression of the renin-angiotensin-aldosterone system could help a broad pool of difficult-to-treat chronic hypertension patients. Instead, the clinical-stage cardiovascular developer is increasingly steering investors, clinicians, and regulators toward a narrower and potentially higher-risk population: patients recovering from acute severe hypertension, where adherence challenges, recurrent blood pressure surges, and the lack of specifically approved post-discharge therapies may create a more defensible path for differentiation.
That matters because the KARDINAL trial did not deliver a clean win on all fronts. Although continued monthly dosing achieved a much greater reduction in angiotensinogen than a single dose, the co-primary blood pressure endpoint between groups was not statistically different. Kardigan attributed that to an unexpected and prolonged blood pressure reduction in the single-dose arm, a result that complicates straightforward interpretation. In biotech terms, this is where the story stops being a press release and starts becoming a credibility test. When a mechanistic biomarker behaves as expected but the comparative clinical endpoint does not separate as planned, observers usually ask whether the biology is real but the trial design was noisy, or whether the biomarker signal is stronger than the clinical value proposition.
Kardigan is clearly betting on the first explanation. The company can reasonably point to dose-dependent angiotensinogen suppression, within-group office systolic blood pressure reductions of 6.7 mmHg in both treatment strategies, and post hoc signals suggesting that patients with higher baseline hypertensive burden may benefit more from sustained dosing. It also highlighted reductions in at-home systolic blood pressure surges above 150 mmHg, a metric that could become strategically important if the company wants to build a case around stabilization rather than just mean office blood pressure change. Those arguments are directionally sensible, but they also shift more weight onto subgroup interpretation and exploratory analyses than regulators or conservative prescribers typically prefer at this stage.
Why the acute severe hypertension angle could matter more than the chronic hypertension readout
The most commercially and clinically significant part of the update may be Kardigan’s insistence that tonlamarsen should now be evaluated in acute severe hypertension after hospitalization. This is a different framing from competing blood pressure therapies that mostly live in the crowded chronic management market, where generic drugs are cheap, combination regimens are familiar, and physicians are not exactly waiting breathlessly for another mechanism unless it delivers clearly superior control, better adherence, or improved outcomes in a hard-to-manage subset.
Acute severe hypertension is a more underdefined and arguably more neglected opportunity. Kardigan described it as a post-hospitalization setting marked by persistent risk, recurrent hypertension, and no indicated therapy specifically approved for ongoing blood pressure management after discharge. That gives the U.S.-based biotech firm a narrative with more urgency and less direct therapeutic clutter. In such a setting, a once-monthly, liver-directed therapy could appeal less as a convenience drug and more as a risk-management tool for a population known to struggle with adherence to daily tablets. That positioning may prove more compelling than trying to force tonlamarsen into the broader resistant hypertension conversation, where clinicians already have multiple classes, spironolactone-based strategies, and growing procedural options such as renal denervation in selected patients.
The challenge, of course, is that a more novel target population also means greater regulatory and clinical uncertainty. Acute severe hypertension after hospitalization is not yet a mainstream commercial category in the same way heart failure, chronic kidney disease, or established resistant hypertension are. For Kardigan, that cuts both ways. It may create room to define the market, but it also means the company may need to do more educational and evidentiary work to persuade regulators that the condition is distinct enough, measurable enough, and important enough to justify targeted development. A therapy cannot simply be innovative; it must land in a clinical workflow that people recognize and can operationalize.
What tonlamarsen’s mechanism says about the next chapter in RAAS targeting
Tonlamarsen’s mechanistic appeal comes from its upstream approach. By targeting hepatic angiotensinogen, the sole precursor of the renin-angiotensin-aldosterone system, the therapy is designed to modulate blood pressure control earlier in the pathway than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In theory, that offers a more foundational intervention and could help in patients whose blood pressure remains unstable despite conventional RAAS modulation. That is the elegant part of the thesis.
The practical part is harder. Mechanistic elegance does not automatically translate into better patient outcomes, especially in hypertension, where modest numerical improvements often struggle to change prescribing behavior unless they bring either a major convenience advantage, strong outcome data, or a clear role in a refractory population. Tonlamarsen being subcutaneous and once monthly is helpful, but injectable chronic cardiovascular therapies still face a higher adoption bar than oral generics. Clinicians will want to know not only whether the drug lowers office blood pressure, but whether it reduces variability, hospital returns, end-organ risk, or the real-world destabilization that follows discharge in acute severe hypertension patients.
That is why the home-based high-density blood pressure data collection component in KARDINAL may deserve more attention than it received in the headline messaging. If Kardigan can show that tonlamarsen reduces dangerous surges and smooths blood pressure control in a way clinic snapshots miss, then the platform could support a broader argument that standard hypertension trial designs may undercapture the value of long-acting gene-silencing or antisense approaches. Still, that remains a future argument, not a settled conclusion.
Why the safety profile helps, but does not yet remove the central development risk
Safety is one of the more reassuring elements of the update. Kardigan said tonlamarsen was generally well tolerated, with worsening renal function uncommon and no meaningful signs of treatment-related hypotension or hyperkalemia. In a field shaped by concerns around renal effects, electrolyte balance, and overtreatment, that matters. A therapy targeting the RAAS axis upstream would immediately draw scrutiny on these issues, so an apparently manageable safety profile at this stage strengthens the case for further development.
But safety alone will not rescue a program if the clinical signal remains hard to interpret. The central development risk is still translational clarity. Tonlamarsen successfully hit its biological target, yet the randomized blood pressure comparison failed to distinguish sustained dosing from the one-dose strategy on a co-primary endpoint. Even if that result reflects trial noise, it means the next study needs to be sharper in patient selection, endpoint design, and clinical relevance. A Phase 2b trial in acute severe hypertension cannot merely repeat the mechanistic story with a slightly different population. It has to prove that this specific post-hospitalization use case creates a more visible and durable clinical benefit.
What clinicians and industry watchers are likely to watch next in the Phase 2b design
The next trial will likely be judged less on whether tonlamarsen lowers a biomarker and more on whether Kardigan can translate a mechanistic signal into a differentiated product profile. Clinicians tracking the field are likely to focus on how acute severe hypertension is operationally defined, how soon after discharge patients are enrolled, what standard-of-care background therapy is permitted, and whether endpoints capture not just mean systolic reduction but recurrence, volatility, rehospitalization risk, or other measures of instability.
Regulatory watchers will also be interested in whether the trial aims for a classical hypertension label logic or something more tailored to post-discharge management. If Kardigan can frame acute severe hypertension as a high-risk transitional care problem with identifiable recurrence patterns and limited pharmacologic options, the company could create a path that is medically credible and commercially differentiated. If not, tonlamarsen risks being seen as an interesting platform asset still searching for the right indication.
For now, the fairest interpretation is that Kardigan has generated encouraging, but not definitive, evidence that tonlamarsen deserves another clinical shot in a more targeted population. The Phase 2 data do not yet establish a practice-changing hypertension therapy. They do, however, suggest that the program may be more valuable as a precision cardiovascular play in unstable, high-risk patients than as a broad chronic hypertension challenger. In other words, tonlamarsen may not be rewriting the blood pressure rulebook yet, but it may be identifying the chapter where it has the best chance of belonging.
Why Kardigan’s Phase 2 tonlamarsen results matter more for acute severe hypertension than chronic blood pressure care added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →